Log in or register to see all Alerts
New HTA Decisions in Germany
December 2020
Drug name
VENCLYXTO® (venetoclax)
Company
AbbVie Deutschland
Decision date
15/10/2020
Therapeutic area
Cancer
Therapeutic sub area
Blood and bone marrow cancers
G-BA decision date
15/10/2020
Orphan Drug?
No
Decision
No additional benefit
Indication
Patients with chronic lymphocytic leukaemia for which therapy with fludarabine in combination with cyclophosphamide and rituximab is not suitable. Main comparator: chlorambucil
Decision Detail
Main study: CLL14 Main driver of decision: Further data submitted by the company, including regarding quality of life, side effects, mortality and morbidity, did not suggest either a negative or positive effect of venetoclax compared to the comparator.
Summary
In this addendum to commission, IQWiG concluded that there was no change in the benefit assessment, which remains no additional benefit.